Home Newsfeeds Baird Downgrades Intel to Neutral, Lowers Price Target to $40

Baird Downgrades Intel to Neutral, Lowers Price Target to $40

Baird analyst Tristan Gerra downgrades Intel (NASDAQ:INTC) from Outperform to Neutral and lowers the price target from $60 to $40.

byBenzinga Newsdesk

July 29, 2022

1 minute read

Baird analyst Tristan Gerra downgrades Intel (NASDAQ:INTC) from Outperform to Neutral and lowers the price target from $60 to $40.

‘Capital One Reportedly Cutting 1,100 Employees As 2023 Layoffs Continue’ – Forbes

By Benzinga Newsdesk

January 19, 4:16 PM

https://www.forbes.com/sites/brianbushard/2023/01/19/capital-one-reportedly-cutting-1100-employees-as-2023-layoffs-continue/?utm_campaign=forbes&utm_source=twitter&utm_medium=social&utm_term=Gordie&sh=6c9

COF

Vaxcyte Exercises Option And Enters Into Manufacturing Rights Agreement With Sutro Biopharma To Obtain Control Over Manufacturing And Development Of Cell-Free Extract For Its Vaccine Candidates

By Benzinga Newsdesk

November 27, 5:01 PM

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement

PCVX